Group items tagged

Existing mouse models of lethal Ebola virus infection do not reproduce hallmark symptoms of Ebola hemorrhagic fever, neither delayed blood coagulation and disseminated intravascular coagulation, nor death from shock, thus restricting pathogenesis studies to non-human primates. Here we show that mice from the Collaborative Cross exhibit distinct disease phenotypes following mouse-adapted Ebola virus infection. Phenotypes range from complete resistance to lethal disease to severe hemorrhagic fever characterized by prolonged coagulation times and 100% mortality. Inflammatory signaling was associated with vascular permeability and endothelial activation, and resistance to lethal infection arose by induction of lymphocyte differentiation and cellular adhesion, likely mediated by the susceptibility allele Tek. These data indicate that genetic background determines susceptibility to Ebola hemorrhagic fever.

A study in monkeys offers the first evidence that a leading drug developed to fight Ebola works against the strain causing the current outbreak in West Africa. Six animals were infected with a very high dose of the virus and then, three days later, half were given the drug, TKM-Ebola-Makona, which was designed specifically to fight the West African strain. The monkeys that received the drug survived, but all three untreated monkeys died, researchers reported on Wednesday in the journal Nature.

The Ebola epidemic that tore through West Africa in 2014 claimed 11,310 lives, far more than any previous outbreak. A combination of factors contributed to its savagery, among them a mobile population, crumbling public health systems, official neglect and hazardous burial practices. But new research suggests another impetus: The virus may have evolved a new weapon against its human hosts. In studies published on Thursday in the journal Cell, two teams of scientists report that a genetic mutation may have made Ebola more deadly by improving the virus's ability to enter human cells.

The number of new Ebola cases is tapering off, but the search for new treatments continues. Now, one research team has found potential drug candidates that successfully treated up to 90 percent of mice exposed to the Ebola virus. They report their findings in the journal ACS Infectious Diseases.

In the wake of a potential global crisis we will investigate the biology of infectious diseases to better understand how they transmit, replicate and induce an immune response in humans. Our objective is to pose solutions to the Ebola outbreak in the United States by studying other infectious diseases. We will investigate infectious diseases and the development of vaccines to show how they have changed the course of human health and populations as a whole. We will determine public perceptions about infectious diseases and identify misconceptions. Ultimately, we will develop community awareness information to manage and in future prevent an outbreak of Ebola.

But this tiny sample turned out to hold tremendous scientific value. It was from a person fortunate to survive the deadly Ebola virus outbreak of 2014. Walker and her colleagues wanted to know if they could identify some special antibodies in that person's blood. If this person had special Ebola-neutralizing antibodies, that might help explain why that person lived. The antibodies might also help provide a template for future development of a vaccine. Or, they could be the basis for genetically engineered copies that could be manufactured at large scale, stockpiled and used to rescue people newly infected in an outbreak.

Ebola is an infectious disease, which has become a pandemic crisis causing around 5000 deaths in 2014, with a 50% mortality rate among those who have contracted the virus. The outbreak in West Africa was first reported in March 2014, and every natural case of Ebola has been in Sub-Saharan Africa with Liberia, Sierra Leone and Guinea at the epicentre of the crisis. This key stage 3-5 resource, produced by GA Consultant and Secondary Phase Committee Co-Chair Stephen Schwab, includes classroom activities and teaching ideas, and explores geographical facts, concepts and the impact the virus has had on the communities affected.

The highly virulent Ebola virus has seen a few major outbreaks since it first appeared in 1976 -- with the worst epidemic occurring in 2014. How does the virus spread, and what exactly does it do to the body? Alex Gendler details what Ebola is and why it's so hard to study.

Controversial new research suggests that contrary to the history books, the "Black Death" that devastated medieval Europe was not the bubonic plague, but rather an Ebola-like virus. History books have long taught the Black Death, which wiped out a quarter of Europe's population in the Middle Ages, was caused by bubonic plague, spread by infected fleas that lived on black rats. But new research in England suggests the killer was actually an Ebola-like virus transmitted directly from person to person.

What does the Ebola virus actually do in your body? Why is it so dangerous and why does it kill so many people? We take a look at the apocalyptic war that rages in the body after an infection by the Ebola virus and the soldiers fighting.

Throughout the last few decades, diseases that spill over from animals to humans have been on the rise. What's behind their increase, and can we do anything to combat these dangerous foes? Join scientists as they investigate the rise of spillover viruses like Zika, Ebola and Nipah, and learn what science can do to anticipate and prevent epidemics around the world.

This case study is based on the 2014 Ebola epidemic that spread to multiple highly populated countries in West Africa, making it the largest and most devastating outbreak in the history of the virus. The storyline, inspired by a compilation of factual information, unfolds through a fictional narrative wherein students play the role of an infectious disease specialist in training to learn about the techniques used in the detection, diagnosis, and management of Ebola virus outbreaks. The story is presented as an interrupted "clicker case" that combines problem-based case teaching methods with simulated biological laboratory inquiry through the use of Case It, a free molecular biology software, along with the NCBI's online bioinformatics tools and databases. Students work in groups to collaboratively explore various biological and social aspects of this infectious disease outbreak. This case was developed for senior students at the secondary level and can be modified for use in an introductory biology, microbiology, or epidemiology course at the undergraduate level.

The highly virulent Ebola virus has seen a few major outbreaks since it first appeared in 1976 -- with the worst epidemic occurring in 2014. How does the virus spread, and what exactly does it do to the body? Alex Gendler details what Ebola is and why it's so hard to study.

The hollow Cola tree growing in a remote area of southeastern Guinea was once home to thousands of bats routinely hunted and killed by the neighborhood children. It was also a popular spot to play. A year ago, one child in particular lived within fifty meters of the tree: a two-year-old boy who died in December 2013 and later was identified as the first person in west Africa known to have developed Ebola.

Behind the unprecedented Ebola outbreak in West Africa lies a species with an incredible power to overtake its host. Zaire ebolavirus and the family of filoviruses to which it belongs owe their virulence to mechanisms that first disarm the immune response and then dismantle the vascular system.

SAN ANTONIO -- Scientists at a South Texas research center made a breakthrough discovery by destroying the Ebola virus in animals through a Chinese herb. Texas Biomedical Research Center said a compound derived from the herb called tetrandrine was used to make a drug. He says his team injected mice with the drug.

In the Oct. 30 edition of Science, scientists describe strains of laboratory mice bred to test the role of an individual's genetic makeup in the course of Ebola disease. Systems biologists and virologists Angela Rasmussen and Michael Katze from the Katze Laboratory at the University of Washington Department of Microbiology led the study in collaboration with the National Institutes of Health's Rocky Mountain Laboratories in Montana and University of North Carolina at Chapel Hill.

WHO factsheet on Ebola

Sub-Saharan Africa is the most genetically diverse region in the world." The rates of susceptibility and not only whether or not someone becomes ill, but also whether or not they live or die, or even display symptoms, varies widely. The genetics of both this deadly strain of Ebola itself, and of the populations living in the affected areas, are at the forefront of the efforts by Dr. Moses as she works with Dr.Pardis Sabeti at Harvard to provide samples for genome sequencing.

In the blood of a survivor of the recent Ebola outbreak, a team of researchers has discovered a number of antibodies that seem to successfully combat the deadly virus in mice. The findings, published in the journal Science, may help point scientists in the right direction for developing a vaccine that could protect against the disease.